Samlyn Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Samlyn Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-118,998	Closed	-$20.2M	–	160
2018 Q2	$20.2M	Sell	118,998 -16,405	-12%	-$2.54M	0.47%	75
2018 Q1	$22.1M	Sell	135,403 -40,760	-23%	-$6.66M	0.48%	73
2017 Q4	$26.4M	Buy	+176,163	New	+$26.1M	0.61%	64
2017 Q2	–	Sell	-45,112	Closed	-$4.93M	–	156
2017 Q1	$4.93M	Sell	45,112 -6,888	-13%	-$606K	0.11%	120
2016 Q4	$3.83M	Buy	+52,000	New	+$4.23M	0.09%	114
2016 Q3	–	Sell	-490,770	Closed	-$42.2M	–	149
2016 Q2	$42.2M	Buy	490,770 +109,770	+29%	+$9.48M	1.01%	39
2016 Q1	$30.3M	Buy	381,000 +62,587	+20%	+$5.66M	0.65%	60
2015 Q4	$40.1M	Buy	+318,413	New	+$38.4M	0.83%	50

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Samlyn Capital's VRTX Position: Q3 2018 in Review

Samlyn Capital sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 118,998 shares — an estimated $20.2M sold.

Samlyn Capital first reported a position in VRTX in Q4 2015 and held it in 8 quarters. The position peaked at $42.2M in Q2 2016. 696 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

Samlyn Capital reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Samlyn Capital sold 118,998 Vertex Pharmaceuticals shares in Q3 2018, an estimated $20.2M.
Samlyn Capital first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 8 quarters.
Samlyn Capital's Vertex Pharmaceuticals position peaked at $42.2M in Q2 2016.
696 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Samlyn Capital's 13F filing for Q3 2018, filed 14 Nov 2018.